Skip to main content

News and blog posts

07
Feb 2019

MTRC has released European reimbursement report for implantable cardioverter defibrillators (ICDs) in 11 EU countries

The report presents a summary of reimbursement situation for implantable cardioverter defibrillators. Both Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) are considered. Use of ICD is considered for ventricular tachycardia and ventricular fibrillation. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
05
Feb 2019

Med Tech-related technology assessments from NICE in December 2018

In December 2018, the National Institute for Health and Care Excellence (NICE) published one new diagnostic guidance (for tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer), two new interventional procedure guidance (for transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults and bronchial thermoplasty for severe asthma), and four MedTech innovation briefings.
04
Feb 2019

MTRC has released European reimbursement report for open replacement of heart valves (all valves) in 11 EU countries

The report presents a summary of reimbursement situation for open replacement of heart valves (aortic, mitral, tricuspid and pulmonary). Report includes information about two types of prosthetic heart valves: biological valves, mechanical prosthetic valves. Open replacement of heart valves will be analyzed in conjunction with open coronary artery bypass grafting (CABG). The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
04
Feb 2019

Update of wearable cardioverter-defibrillator (WCD) therapy assessment in Austria

In January 2019, the Austrian HTA body Ludwig-Boltzmann Institute (LBI) has published the update of their decision support document (DSD) 103, which concerns the wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. The authors state that further research is necessary for the development of reliable conclusions.
29
Jan 2019

Five new procedure codes added to private reimbursement schedule in England in October/November 2018

The Clinical Coding and Schedule Development (CCSD) group develops and maintains procedural and diagnostics nomenclature for private payers in England. In October/November 2018, five new procedure codes for laser correction of refractive error following non-refractive ophthalmic surgery, insertion of urethral catheterization device, injection of botulinum toxin for hyperhidrosis, laparoscopic and robotic-assisted pancreatoduodenectomy have been added to the CCSD Schedule.